For a comprehensive understanding of the genes involved in acquired resistance to trastuzumab in HER2-positive breast cancer, we analyzed the gene expression profile of BT-474 and BT-474.r2T cells using Affymetrix microarrays. This evidence concerns the gene ERBB2 and breast carcinoma.